- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
In connection with a proposed public offering of shares of common stock directly to institutional investors pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission, we have determined that our net asset value per share as of June 14, 2007, was $5.28.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities referred to herein, nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Investors are advised to carefully consider the investment objectives, risks and charges and expenses of the Company before investing. The prospectus dated May 11, 2007, and the preliminary prospectus supplement dated June 14, 2007, contain this and other information about the Company and should be read carefully before investing. An offering may be made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained from Harris & Harris Group, Inc., 111 West 57th Street, Suite 1100, New York, NY 10019, at (212) 582-0900 or from Global Crown Capital, LLC at 101 California Street, Suite 4550, San Francisco, CA 94111.
About Harris & Harris Group
Harris & Harris Group is a publicly traded venture capital company that makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 34 initial private equity investments have been in tiny technology-enabled companies. The Company had 21,806,896 shares of common stock outstanding as of June 14, 2007.
Detailed information about Harris & Harris Group and its holdings can be found on its website at http://www.TinyTechVC.com .
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Registration Statement on Form N-2, Prospectus Supplement and Annual Report on Form 10-K for the year ended December 31, 2006, as well as subsequent SEC filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc., undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference to the website http://www.TinyTechVC.com has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
For more information, please click here
Harris & Harris Group, Inc.
Charles E. Harris, 212-582-0900
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Scientists create laser-activated superconductor February 8th, 2016
Canadian physicists discover new properties of superconductivity February 8th, 2016
Leading bugs to the death chamber: A kinder face of cholesterol February 8th, 2016
From allergens to anodes: Pollen derived battery electrodes February 8th, 2016
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015